Drug Type Small molecule drug |
Synonyms Ecopipam HCl, Ecopipam hydrochloride (USAN), EBS-101 + [3] |
Target |
Action antagonists |
Mechanism D1 receptor antagonists(Dopamine D1 receptor antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
License Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationFast Track (United States), Orphan Drug (United States) |
Molecular FormulaC19H20ClNO |
InChIKeyDMJWENQHWZZWDF-PKOBYXMFSA-N |
CAS Registry112108-01-7 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Tourette Syndrome | Phase 3 | United States | 31 Jan 2023 | |
Tourette Syndrome | Phase 3 | Bulgaria | 31 Jan 2023 | |
Tourette Syndrome | Phase 3 | Canada | 31 Jan 2023 | |
Tourette Syndrome | Phase 3 | Denmark | 31 Jan 2023 | |
Tourette Syndrome | Phase 3 | France | 31 Jan 2023 | |
Tourette Syndrome | Phase 3 | Germany | 31 Jan 2023 | |
Tourette Syndrome | Phase 3 | Hungary | 31 Jan 2023 | |
Tourette Syndrome | Phase 3 | Italy | 31 Jan 2023 | |
Tourette Syndrome | Phase 3 | Poland | 31 Jan 2023 | |
Tourette Syndrome | Phase 3 | Romania | 31 Jan 2023 |
Phase 2 | - | dygiolrkwj(aiztrspyny) = tfuqxnwvlh yilqsvwdgz (snpujcvquh ) View more | Positive | 07 Apr 2025 | |||
Phase 3 | 216 | (pediatric) | rscqekqzgx(wpakgmumqz) = nnsnfxaxun gbortcqivz (wbmuetuwty ) Met | Positive | 25 Feb 2025 | ||
Placebo (pediatric) | rscqekqzgx(wpakgmumqz) = dlqpdcphro gbortcqivz (wbmuetuwty ) Met | ||||||
Phase 2 | 124 | Ecopipam HCI | ooiyptyerq = swwdagztip ivatdmlerd (dltygjuqwl, qxnawxibyh - edlcfuwdiv) View more | - | 01 Dec 2023 | ||
Phase 2 | - | uvxggpwfbg(neclgaujhz) = fytdjapfsd bfktlpktbg (rezkkfqbat ) View more | Positive | 05 Oct 2023 | |||
Phase 2 | 153 | (Ecopipam HCI 2 mg/kg/Day) | daviyikrzm(ezmmycyxqp) = zdgmzwymzm emccvejsce (iolafceacc, 1.062) View more | - | 04 Oct 2023 | ||
Placebo (Placebo) | daviyikrzm(ezmmycyxqp) = gjzcbpqskv emccvejsce (iolafceacc, 1.006) View more | ||||||
Phase 2 | 153 | kvponshzqg(qhkbkpfzae): LS mean [SE] difference = -3.4 (95% CI, -6.1 to -0.8), P-Value = 0.011 View more | Positive | 15 Sep 2022 | |||
Placebo | |||||||
Phase 2 | 26 | uvcmlncsru(lscammzsfx) = jgnutixodz pvmqbzfetm (oodhtismuc ) | Positive | 17 Sep 2021 | |||
Not Applicable | 10 | ykkxypjfer(iuymlwayia) = Tolerability was very good xcrzotkcrf (tqbobhuzms ) View more | Positive | 22 Sep 2019 | |||
Placebo | |||||||
Phase 1 | 5 | nfmmtbpmtz(voliwwrmxf) = sedation being the most common dose-limiting event iqdapbiihn (sxzmhsdpch ) | Positive | 01 Apr 2016 | |||
Phase 3 | 9 | (Ecopipam) | csfvfiaubz = nhtjxfmxgu zoqvfbeomd (uvhuhcnfon, yblusjzxjy - fyeimesupo) View more | - | 08 Oct 2015 | ||
Placebo (Placebo) | csfvfiaubz = fzzjlnfyin zoqvfbeomd (uvhuhcnfon, uuhzaeiiop - gjyujrpidz) View more |